Send to

Choose Destination
See comment in PubMed Commons below
Eur Urol. 2010 Aug;58(2):311-2.

Words of wisdom. Re: Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Morris MJ, Huang D, Kelly WK, et al. Eur Urol 2009;56:237-44.

Author information

Department of Urology, University of Washington, Seattle, Washington, USA.


Laboratory studies suggest that castration-resistant prostate cancer (CRPC) cell growth is suppressed by supraphysiologic doses of testosterone (T). In this study, 12 men received high doses of T transdermally for 7 d, for 4 mo, or until progression.The approach was safe and toxicity was mild, but responses were modest. Because serum T did not reach intended supraphysiologic levels, the authors urged more clinical testing.

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center